NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets

GlobeNewswireNov 13 16:14 ET

NurExone's Innovative Therapies Gain Recognition

TipRanksOct 23 03:04 ET

NurExone's ExoPTEN, Loaded With SiRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

GlobeNewswireAug 9 16:04 ET

NurExone Announces Further Expansion of ExoPTEN Patent Coverage

GlobeNewswireJul 29 16:04 ET

Updates From NurExone: Growth Conference Presentation and Website Relaunch

GlobeNewswireJul 5 08:43 ET

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

GlobeNewswireJun 21 16:04 ET